Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04928846 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 698
- Enrollment target
- 20
- Study locations
NCT04928846 is a Phase 3 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by AbbVie. The registered enrollment target is 698 participants, roughly in line with the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The trial reports 20 study locations across 8 states.
The verdict
NCT04928846, a Phase 3 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 698 participants
- Enrollment target
- 20
- Study locations
Study Summary
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine if telisotuzumab vedotin works better than docetaxel and to assess how safe telisotuzumab vedotin is in adult participants with NSCLC who have previously been treated. Change in disease activity and adverse events will be assessed. Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of Teliso-V or Docetax at an 1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin or IV infusion of docetaxel. Approximately 698 adult participants with c-Met overexpressing NSCLC will be enrolled in the study in approximately 330 sites worldwide. Participants will receive IV telisotuzumab vedotin every 2 weeks or docetaxel every 3 weeks until meeting study drug discontinuation criteria. At the conclusion of the study, participants who continue to demonstrate clinical benefit may be eligible to receive study treatment via an extension of the study, a rollover study, or through another mechanism. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions Studied
Interventions
- DRUG Docetaxel
- BIOLOGICAL Telisotuzumab Vedotin
Study Locations (20)
California
- City of Hope /ID# 243157 - Duarte
- City Of Hope - Seacliff /ID# 263143 - Huntington Beach
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 263144 - Irvine
- City Of Hope - Antelope Valley /ID# 263138 - Lancaster
- The Oncology Institute Of Hope & Innovation -East Los A /ID# 239774 - Los Angeles
- University of California, Los Angeles /ID# 253954 - Los Angeles
- Eisenhower Medical Center /ID# 233189 - Rancho Mirage
Arizona
- Ironwood Cancer & Res Ctr /ID# 262446 - Chandler
- Mayo Clinic Arizona /ID# 255858 - Phoenix
- Onvida Health Yuma Medical Center /ID# 253625 - Yuma
Florida
- Mayo Clinic Hospital Jacksonville /ID# 254688 - Jacksonville
- Ocala Oncology Florida Cancer Affiliates - Main /ID# 234228 - Ocala
- BRCR Medical Center Inc /ID# 262344 - Tamarac
Illinois
- Edward-Elmhurst Cancer Center /ID# 238552 - Elmhurst
- Springfield Clinic - First /ID# 262290 - Springfield
Indiana
- Goshen Center for Cancer Care /ID# 257734 - Goshen
- Investigative Clinical Research of Indiana - Indianapolis /ID# 260468 - Indianapolis
Alabama
- University of Alabama at Birmingham - Main /ID# 247074 - Birmingham
Georgia
- Memorial University Medical Center /ID# 264081 - Savannah
Hawaii
- Kaiser Permanente Moanalua Medical Center /ID# 238363 - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 698 participants |
| Start Date | 2022-03-25 |
| Est. Completion | 2028-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04928846
The ClinicalTrials.gov registry entry for NCT04928846 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 698 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Docetaxel is the first listed.
NCT04928846 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT04928846 about?
NCT04928846 is a clinical study titled "A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)". Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine if telisotuzumab vedotin works better than d...
What is the current status of trial NCT04928846?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 698 participants. The study started on 2022-03-25. Estimated completion is 2028-03.
What conditions does trial NCT04928846 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT04928846?
The interventions under investigation include: Docetaxel (DRUG), Telisotuzumab Vedotin (BIOLOGICAL).
Who is sponsoring clinical trial NCT04928846?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04928846 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.